[
  {
    "ts": null,
    "headline": "TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary",
    "summary": "TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=4e08f93212ff37a990ca19adb459a906001e6fc7b0dfd5f9b6a999245c346c30",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745420280,
      "headline": "TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary",
      "id": 134045979,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4e08f93212ff37a990ca19adb459a906001e6fc7b0dfd5f9b6a999245c346c30"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=0b0f04ebb88071a91e76db816c198189436a6e4a9acf35ad22ffc29a8fa6883b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745415608,
      "headline": "Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term",
      "id": 134046305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=0b0f04ebb88071a91e76db816c198189436a6e4a9acf35ad22ffc29a8fa6883b"
    }
  },
  {
    "ts": null,
    "headline": "2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market",
    "summary": "2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market",
    "url": "https://finnhub.io/api/news?id=d95473ce6d5c40ead5673ea4913858101d82b94ef532021f9bd4bb9ef31c7056",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745402288,
      "headline": "2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market",
      "id": 134044306,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d95473ce6d5c40ead5673ea4913858101d82b94ef532021f9bd4bb9ef31c7056"
    }
  },
  {
    "ts": null,
    "headline": "European pharma companies push for higher drug prices in EU amid U.S. tariff threats",
    "summary": "(Reuters) -European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, the bloc would fall further behind the U.S., where tariff threats have triggered a wave of pharma investment announcements.  AstraZeneca Chief Executive Officer Pascal Soriot said that just like Europe has stepped up its defense spending, it now must do the same and invest more to protect its health sovereignty amid a shifting world order.  \"Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk,\" Soriot said in a statement.",
    "url": "https://finnhub.io/api/news?id=eeab42fd3a21b354653bf7a401e5311bfbc7c019c6f38cd220d8cbca9cbbaa66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745390660,
      "headline": "European pharma companies push for higher drug prices in EU amid U.S. tariff threats",
      "id": 134046306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Reuters) -European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, the bloc would fall further behind the U.S., where tariff threats have triggered a wave of pharma investment announcements.  AstraZeneca Chief Executive Officer Pascal Soriot said that just like Europe has stepped up its defense spending, it now must do the same and invest more to protect its health sovereignty amid a shifting world order.  \"Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk,\" Soriot said in a statement.",
      "url": "https://finnhub.io/api/news?id=eeab42fd3a21b354653bf7a401e5311bfbc7c019c6f38cd220d8cbca9cbbaa66"
    }
  },
  {
    "ts": null,
    "headline": "Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns",
    "summary": "Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns",
    "url": "https://finnhub.io/api/news?id=eaac6e9c845c2f82b606d3d73abdf9f438e0115f65507451348e00074b95c29c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745379600,
      "headline": "Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns",
      "id": 134041757,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eaac6e9c845c2f82b606d3d73abdf9f438e0115f65507451348e00074b95c29c"
    }
  },
  {
    "ts": null,
    "headline": "JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations",
    "summary": "Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=56bd12fccd59e90180df0edf843a9895254a63936605c5e1d320360f778e5d29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745376873,
      "headline": "JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations",
      "id": 134038785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=56bd12fccd59e90180df0edf843a9895254a63936605c5e1d320360f778e5d29"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Johnson & Johnson, Chevron, and Flowers Foods have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 3% to 5%. Johnson & Johnson Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. Don't Miss: Delo",
    "url": "https://finnhub.io/api/news?id=97147fb9bbaab84d334d0caae15bb371c4f2d176cd52716d7089992dcedfe705",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745373668,
      "headline": "Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income",
      "id": 134038786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Johnson & Johnson, Chevron, and Flowers Foods have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 3% to 5%. Johnson & Johnson Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. Don't Miss: Delo",
      "url": "https://finnhub.io/api/news?id=97147fb9bbaab84d334d0caae15bb371c4f2d176cd52716d7089992dcedfe705"
    }
  }
]